[go: up one dir, main page]

WO2001047528A3 - Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete - Google Patents

Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete Download PDF

Info

Publication number
WO2001047528A3
WO2001047528A3 PCT/FR2000/003600 FR0003600W WO0147528A3 WO 2001047528 A3 WO2001047528 A3 WO 2001047528A3 FR 0003600 W FR0003600 W FR 0003600W WO 0147528 A3 WO0147528 A3 WO 0147528A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating diabetes
glycosidase inhibitors
pharmacological uses
glucose
polyamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2000/003600
Other languages
English (en)
Other versions
WO2001047528A2 (fr
Inventor
Nushin Banu Helene Aghajari
Xavier Guy Robert
Richard Michel Haser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Original Assignee
Centre National de la Recherche Scientifique CNRS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS filed Critical Centre National de la Recherche Scientifique CNRS
Priority to JP2001548121A priority Critical patent/JP2003518501A/ja
Priority to CA002395305A priority patent/CA2395305A1/fr
Priority to EP00990069A priority patent/EP1239863A2/fr
Priority to AU26873/01A priority patent/AU2687301A/en
Publication of WO2001047528A2 publication Critical patent/WO2001047528A2/fr
Publication of WO2001047528A3 publication Critical patent/WO2001047528A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour object l'utilisation d'un dérivé de polyamine ou d'une polyamine pour inhibir le site actif des enzymes glycosidases intervenant dans la transformation de polysaccharides en sucres, notamment en glucose, dans un organisme vivant et l'utilisation d'un dérivé de polyamine ou d'une polyamine pour la préparation d'un medicament destiné au diagnostic, à la prévention ou au traitement de phathologies inpliquant des désordres métaboliques liés aux glycosidases, et plus particulièrement une dérégulation de l'absorption intestinale de glucose, telles que le diabète non-insulino dépendant, l'obésité, l'hyperglycémie, ou l'hyperlipidémie.
PCT/FR2000/003600 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete Ceased WO2001047528A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001548121A JP2003518501A (ja) 1999-12-23 2000-12-20 新規なグリコシダーゼ阻害剤および特に糖尿病を治療するためのその薬理学的使用
CA002395305A CA2395305A1 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
EP00990069A EP1239863A2 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
AU26873/01A AU2687301A (en) 1999-12-23 2000-12-20 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR99/16409 1999-12-23
FR9916409A FR2802817B1 (fr) 1999-12-23 1999-12-23 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Publications (2)

Publication Number Publication Date
WO2001047528A2 WO2001047528A2 (fr) 2001-07-05
WO2001047528A3 true WO2001047528A3 (fr) 2002-06-20

Family

ID=9553772

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2000/003600 Ceased WO2001047528A2 (fr) 1999-12-23 2000-12-20 Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete

Country Status (7)

Country Link
US (1) US20030143713A1 (fr)
EP (1) EP1239863A2 (fr)
JP (1) JP2003518501A (fr)
AU (1) AU2687301A (fr)
CA (1) CA2395305A1 (fr)
FR (1) FR2802817B1 (fr)
WO (1) WO2001047528A2 (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030013772A1 (en) * 2000-02-23 2003-01-16 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
US20050085555A1 (en) * 1997-08-21 2005-04-21 Murphy Michael A. Composition, synthesis and therapeutic applications of polyamines
EP1173223A2 (fr) 1999-04-30 2002-01-23 Slil Biomedical Corporation Nouveaux conjugues d'analogue de polyamine et conjugues de quinone, utilises pour le traitement de cancers et de maladies de la prostate
AU4679900A (en) * 1999-04-30 2000-11-17 Slil Biomedical Corporation Conformationally restricted polyamine analogs as disease therapies
AU2001297817A1 (en) 2000-11-08 2002-11-25 Eli Lilly And Company Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
JP2005506354A (ja) * 2001-10-16 2005-03-03 スリル バイオメディカル コーポレイション 癌治療のためのオリゴアミン化合物およびその誘導体
JP2004189714A (ja) * 2002-12-09 2004-07-08 Rasanen Tiina-Liisa すい臓炎の治療と予防ならびに肝臓再生機能の誘導のための薬剤
CA2623025A1 (fr) 2005-09-20 2007-03-29 Schering Corporation La 1- [ [1- [ (2-amin0-6-methyl-4-pyridinyl) methyl] -4-flu0r0-4-piperidinyl,] carbonyl] -4- [2- (2-pyridinyl) -3h-imidaz0 [4, 5-b] pyridin-3-yl] piperidine, utile en tant qu'antagoniste de l'histamine h3
ES2559319T3 (es) 2007-06-04 2016-02-11 Synergy Pharmaceuticals Inc. Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
FR2917971B1 (fr) 2007-06-28 2009-10-23 Engelhard Lyon Soc Par Actions Composition amincissante
US8153611B2 (en) * 2007-06-28 2012-04-10 Basf Beauty Care Solutions France S.A.S. Use of sulfated oligosaccharides as slimming cosmetic ingredients
ES2700111T3 (es) * 2007-06-28 2019-02-14 Basf Beauty Care Solutions France Sas Composición adelgazante
MX2010004450A (es) 2007-10-22 2010-05-05 Schering Corp Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119.
US20110065671A1 (en) 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
CA2726917C (fr) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
EP3241839B1 (fr) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres
RU2392933C2 (ru) * 2008-07-18 2010-06-27 Учреждение Российской Академии Медицинских Наук Научно-исследовательский институт экспериментальной медицины Северо-западного отделения РАМН (НИИЭМ СЗО РАМН) Средство, обладающее гиполипидемическими свойствами
EP2318388A2 (fr) 2008-07-23 2011-05-11 Schering Corporation Dérivés spirocycliques tricycliques et leurs procédés d utilisation
CA2738663A1 (fr) 2008-10-03 2010-04-08 Schering Corporation Derives de spiro-imidazolone utilises en tant qu'antagonistes des recepteurs du glucagon
AU2009303444A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
US20110245209A1 (en) 2008-12-16 2011-10-06 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (fr) 2008-12-16 2011-10-26 Schering Corporation Dérivés de pyranone bicyclique comme agonistes du récepteur de l'acide nicotinique
EP2379565A1 (fr) 2008-12-19 2011-10-26 Schering Corporation Dérivés de pipéridine et de pipérazine et leurs méthodes d'utilisation
EP2379564A1 (fr) 2008-12-19 2011-10-26 Schering Corporation Dérivés hétérocycliques bicycliques et leurs procédés d'utilisation
EP2382204B1 (fr) 2008-12-23 2018-07-11 Merck Sharp & Dohme Corp. Dérivés de pyrimidine en tant que modulateurs de rcpg pour une utilisation d'un traitement de l'obésité et du diabète
EP2382203B1 (fr) 2008-12-23 2015-01-14 Merck Sharp & Dohme Corp. Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
WO2010075273A1 (fr) 2008-12-23 2010-07-01 Schering Corporation Dérivés d'hétérocycles bicycliques et leurs procédés d'utilisation
EP2408766A1 (fr) 2009-03-18 2012-01-25 Schering Corporation Composés bicycliques en tant qu'inhibiteurs de la diacylglycérol acyltransférase
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
WO2010114957A1 (fr) 2009-04-03 2010-10-07 Schering Corporation Dérivés de pipéridine et de pipérazine bicycliques en tant que modulateurs de rcpg pour le traitement de l'obésité, du diabète et d'autres troubles métaboliques
US8470773B2 (en) 2009-06-12 2013-06-25 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
WO2011031628A1 (fr) 2009-09-14 2011-03-17 Schering Corporation Inhibiteurs de diacylglycérol acyltransférase
EP2485735B1 (fr) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibiteurs de protéines de liaison aux acides gras (fabp)
WO2011053688A1 (fr) 2009-10-29 2011-05-05 Schering Corporation Dérivés de pipéridine bicycliques pontés et leurs procédés d'utilisation
US8912206B2 (en) 2009-11-23 2014-12-16 Merck Sharp & Dohme Corp. Pyrimidine ether derivatives and methods of use thereof
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
EP2503887B1 (fr) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Dérivés de biaryle substitué et leurs procédés d'utilisation
WO2011113060A2 (fr) * 2010-03-12 2011-09-15 Trana Discovery, Inc. Composés antiviraux et procédés d'utilisation de ceux-ci
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
ITMI20130555A1 (it) * 2013-04-09 2014-10-10 Giuliani Spa Composizione farmaceutica o cosmetica per contrastare l¿invecchiamento della pelle attraverso un¿azione antiinfiammatoria
EA201592263A1 (ru) 2013-06-05 2016-05-31 Синерджи Фармасьютикалз, Инк. Ультрачистые агонисты гуанилатциклазы c, способ их получения и использования

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2014613A1 (fr) * 1968-07-15 1970-04-17 Bayer Ag
US4536493A (en) * 1981-06-13 1985-08-20 Baker Aktiengesellschaft Saturated aminocyclitol derivatives, their preparation and medicaments containing these compounds
WO1989008098A2 (fr) * 1988-02-19 1989-09-08 The Upjohn Company Polyamines lipophiles utiles pour traiter l'hypercholesterolemie
EP0370994A2 (fr) * 1988-11-25 1990-05-30 Gert Prof. Dr. Lubec Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine
EP0395357A2 (fr) * 1989-04-28 1990-10-31 Pfizer Inc. Polyamines utiles comme antagonistes des neurotransmetteurs excitables par aminoacides et/ou comme bloqueurs des canaux de calcium
WO1992017216A1 (fr) * 1991-04-02 1992-10-15 Advanced Magnetics, Inc. Administration d'agents de contraste radiographiques a l'aide de l'endocytose a mediation par recepteurs
WO1994012464A1 (fr) * 1992-12-03 1994-06-09 Charonis Aristidis S Role protecteur des polyamines lors de modifications des macromolecules des couches sous-epitheliales
EP0839826A2 (fr) * 1996-10-29 1998-05-06 Coöperatieve Weiproduktenfabriek "Borculo" W.A. Amines et amides de sucre et leur application comme gomme
WO1999021542A2 (fr) * 1997-10-27 1999-05-06 The Regents Of The University Of California Procedes pour moduler la proliferation des macrophages au moyen d'analogues de polyamine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4228274A (en) * 1976-09-28 1980-10-14 Merck & Co., Inc. 1-Substituted glycopyranosides
US5077313A (en) * 1988-11-25 1991-12-31 Gert Lubec Process for inhibiting pathological collagen cross-linking in diabetes patients
US5744453A (en) * 1996-01-05 1998-04-28 Mintz; Clifford S. Polyamine conjugates for treatment of infection

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2014613A1 (fr) * 1968-07-15 1970-04-17 Bayer Ag
US4536493A (en) * 1981-06-13 1985-08-20 Baker Aktiengesellschaft Saturated aminocyclitol derivatives, their preparation and medicaments containing these compounds
WO1989008098A2 (fr) * 1988-02-19 1989-09-08 The Upjohn Company Polyamines lipophiles utiles pour traiter l'hypercholesterolemie
EP0370994A2 (fr) * 1988-11-25 1990-05-30 Gert Prof. Dr. Lubec Traitement de liaisons transversales du collagène, initiées par le glucose chez les diabétiques, par l'arginine, la spermidine, la créatine ou l'agmatine
EP0395357A2 (fr) * 1989-04-28 1990-10-31 Pfizer Inc. Polyamines utiles comme antagonistes des neurotransmetteurs excitables par aminoacides et/ou comme bloqueurs des canaux de calcium
WO1992017216A1 (fr) * 1991-04-02 1992-10-15 Advanced Magnetics, Inc. Administration d'agents de contraste radiographiques a l'aide de l'endocytose a mediation par recepteurs
WO1994012464A1 (fr) * 1992-12-03 1994-06-09 Charonis Aristidis S Role protecteur des polyamines lors de modifications des macromolecules des couches sous-epitheliales
EP0839826A2 (fr) * 1996-10-29 1998-05-06 Coöperatieve Weiproduktenfabriek "Borculo" W.A. Amines et amides de sucre et leur application comme gomme
WO1999021542A2 (fr) * 1997-10-27 1999-05-06 The Regents Of The University Of California Procedes pour moduler la proliferation des macrophages au moyen d'analogues de polyamine

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
ANDERSON, D. J.; SHAW, G. G.: "Hyperglycemia produced by the polyamines spermine and spermidine", BR. J. PHARMACOL., vol. 52, no. 2, 1974, pages 205 - 211, XP000861980 *
DUA R D ET AL: "ACTIVATION OF SOLUBLE AND IMMOBILIZED ALPHA AMYLASE HOG PANCREAS BY POLY CATIONS", JOURNAL OF MOLECULAR CATALYSIS, vol. 7, no. 4, 1980, pages 443 - 456, XP000912051, ISSN: 0304-5102 *
FITZGERALD, PAULA M. D. ET AL: "Improvement of limit of diffraction and useful x-ray lifetime of crystals of glycogen debranching enzyme", J. CRYST. GROWTH (1986), 76(3), 600-6, XP000938611 *
JOHNSON LEONARD R ET AL: "Polyamines alter intestinal glucose transport.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 268, no. 3 PART 1, 1995, pages G416 - G423, XP000912052, ISSN: 0002-9513 *
KEEGAN A ET AL: "METAL CHELATOR AND FREE RADICAL SCAVENGER TREATMENTS PREVENT CHRONIC AORTA RELAXATION DEFECTS IN DIABETIC RATS", DIABETOLOGIA, BERLIN, DE, vol. 39, no. SUPPL 1, 1996, pages ABS909, XP000870277, ISSN: 0012-186X *
KOHNO H ET AL: "EFFECTS OF INTRA PERITONEALLY ADMINISTERED SPERMINE ON INGESTIVE BEHAVIOR SERUM GLUCOSE AND FREE FATTY-ACID CONCENTRATIONS IN RATS.", FOLIA PHARMACOL JPN, (1981) 77 (4), 361-370., XP000861875 *
KOHNO, HIROYUKI ET AL: "Changes in ingestive behavior, serum glucose and free fatty acids concentrations in rats following intracerebroventricular injection of spermine", JPN. J. PHARMACOL. (1981), 31(6), 863-73, XP000861876 *
LAUE C ET AL: "Polyamines may induce proliferation and apoptosis of islet cells in a dose dependent manner.", DIABETOLOGIA, vol. 41, no. SUPPL. 1, August 1998 (1998-08-01), 34th Annual Meeting of the European Association for the Study of Diabetes;Barcelona, Spain; September 11, 1998, pages A161, XP000911951, ISSN: 0012-186X *
MARCH, JAMES E.: "Spermine induced hyperglycemia in the intact rat. Effects on glucose-6-phosphatase, phosphorylase, and liver glycogen", DISS. ABSTR, vol. 27, no. 12, 1967, pages 4541, XP000861899 *
MARX, M. ET AL: "Agmatine and spermidine reduce collagen accumulation in kidneys of diabetic db/db mice", NEPHRON (1995), 69(2), 155-8, XP000861984 *
MENDEZ JOSE D ET AL: "Prevention by L-arginine and polyamines of delayed development and embryotoxicity caused by chemically-induced diabetes in rats.", REPRODUCTIVE TOXICOLOGY, vol. 13, no. 6, November 1999 (1999-11-01), pages 501 - 509, XP000861818, ISSN: 0890-6238 *
PAVLOVIC D ET AL: "In vitro and in vivo evaluation of polyamines inhibitory effect on oxidative stress in experimental diabetes mellitus.", DIABETOLOGIA, vol. 40, no. SUPPL. 1, 1997, 16th International Diabetes Federation Congress;Helsinki, Finland; July 20-25, 1997, pages A370, XP000912200, ISSN: 0012-186X *
RAMESH V ET AL: "STUDIES ON THE KINETICS AND ACTIVATION OF SOLUBLE AND IMMOBILIZED SWEET-POTATO BETA AMYLASE", JOURNAL OF MOLECULAR CATALYSIS, vol. 10, no. 3, 1981, pages 341 - 356, XP000911927, ISSN: 0304-5102 *
SAITO Y ET AL: "SYNTHESIS OF N-1-P GLYCOSYLOXYCINNAMOYLSPERMIDINES", CARBOHYDRATE RESEARCH, vol. 169, 1987, pages 171 - 188, XP000938591, ISSN: 0008-6215 *
SINGH C ET AL: "EFFECT OF BIOLOGICALLY OCCURRING POLY CATIONIC COMPOUNDS ON SOME OF THE PANCREATIC ACTIVITIES", INDIAN JOURNAL OF EXPERIMENTAL BIOLOGY, vol. 18, no. 8, 1980, pages 899 - 901, XP000961803, ISSN: 0019-5189 *
SJOHOLM AKE: "Role of polyamines in the regulation of proliferation and hormone production by insulin-secreting cells.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 264, no. 3 PART 1, 1993, pages C501 - C518, XP000911967, ISSN: 0002-9513 *
TSOPANOGLOU NICOS E ET AL: "Putrescine: A novel inhibitor of glycosylation-induced cross-links in laminin.", MICROCIRCULATION (NEW YORK), vol. 2, no. 3, 1995, pages 283 - 287, XP000861898, ISSN: 1073-9688 *
ZUBER GUY ET AL: "Enhanced ligation of DNA with a synthetic effector molecule.", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 115, no. 11, 1993, pages 4939 - 4940, XP002146826, ISSN: 0002-7863 *

Also Published As

Publication number Publication date
US20030143713A1 (en) 2003-07-31
FR2802817B1 (fr) 2002-10-11
EP1239863A2 (fr) 2002-09-18
JP2003518501A (ja) 2003-06-10
WO2001047528A2 (fr) 2001-07-05
CA2395305A1 (fr) 2001-07-05
AU2687301A (en) 2001-07-09
FR2802817A1 (fr) 2001-06-29

Similar Documents

Publication Publication Date Title
WO2001047528A3 (fr) Nouveaux inhibiteurs de glycosidases et leurs applications pharmacologiques, notamment pour traiter le diabete
WO2006034489A3 (fr) Inhibiteurs de c-aryl glucoside sglt2 et methode
US10350229B2 (en) Use of lactulose in the treatment of autism
CA2281001A1 (fr) Production microbienne de 1,2-propanediols a partir de sucre
DE69633502D1 (de) Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit
WO2000067734A3 (fr) Utilisation de derives de phtalazine
MX2011008416A (es) Medicaciones antidiabeticas que comprenden un inhibidor de dpp-4 (linagliptina) opcionalmente en combinacion con otros antidiabeticos.
Kim et al. Isolation and characterization of α-glucosidase inhibitor from the fungus Ganoderma lucidum
Gore et al. The 10-year post-trial follow-up of the United Kingdom Prospective Diabetes Study (UKPDS): cardiovascular observations in context
WO2003032994A3 (fr) Nouvelles pyrimidines substituees, procede permettant de les produire et leur utilisation comme medicament
WO2002038794A3 (fr) Cibles diagnostiques et therapeutiques pour maladies cardio-vasculaires
WO2006034225A3 (fr) Production d'oligosaccharides par des micro-organismes
WO2004072031A8 (fr) Composes d'amides substitues tri(cyclo)
WO2003086452A3 (fr) Procedes permettant d'ameliorer le traitement de maladies lysosomales
WO2003094856A3 (fr) 1l1rl-1 utilise comme marqueur de maladies cardio-vasculaires et cible therapeutique
EP1889614A3 (fr) Procédés d'utilisation d'inhibiteurs de récapture de la sérotonine sélective à départ rapide pour le traitement de dysfonctionnements sexuels
WO2002011743B1 (fr) Traitement du cancer de la prostate
NO20054408L (no) 3(2-fenyl-oksazol-4-yl-metoksy)-cykloheksylmetoksyeddiksyrederivater og lignende forbindelser som PPAR-modulatorer for behandling av type 2 diabetes og arterosklerose
BR0015102A (pt) Bactérias de ácido latico para o tratamento e/ou profilaxia de giardìase
WO2000051644A8 (fr) Traitement de la diarrhee provoquee par escherichia coli enteropathogenes
WO2001026639A3 (fr) Procede de traitement de troubles du metabolisme
CA2255668A1 (fr) Extrait purifie d'harpagophytum procumbens et/ou d'harpagophytum zeyheri dence, procede permettant de le preparer et utilisation
US8309079B2 (en) Use of fructanases in feed of hoofed animals, preferably to prevent diseases
AU2003269944A1 (en) Mechanisms of myoblast transfer in treating heart failure
WO2003054208A3 (fr) Procede permettant de moduler la liberation de saccharides et utilisations dudit procede

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000990069

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2395305

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 548121

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 2000990069

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10168703

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000990069

Country of ref document: EP